These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10573320)

  • 41. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological treatment of tardive dyskinesia: recent developments.
    Caroff SN; Campbell EC; Carroll B
    Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms.
    An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Lv MH; Zhou DF; Soares JC; Kosten TR; Yang FD; Zhang XY
    Behav Brain Res; 2016 Jan; 297():124-30. PubMed ID: 26455874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Partial reversal of the iminodipropionitrile-induced hyperkinetic syndrome in rats by alpha-tocopherol (vitamin E).
    Lohr JB; Cadet JL; Wyatt RJ; Freed WJ
    Neuropsychopharmacology; 1988 Dec; 1(4):305-9. PubMed ID: 3251508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tardive Dyskinesia.
    Tarsy D
    Curr Treat Options Neurol; 2000 May; 2(3):205-214. PubMed ID: 11096748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review.
    Driesens F
    Acta Psychiatr Belg; 1988; 88(3):195-205. PubMed ID: 2906780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventing neuroleptic-induced tardive dyskinesia in adults and children.
    Lam RW; Jeste SD; Jeste DV
    Encephale; 1988 Sep; 14 Spec No():251-5. PubMed ID: 2905652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia.
    Browne J; Silver H; Martin R; Hart R; Mergener M; Williams P
    J Clin Psychopharmacol; 1986 Apr; 6(2):88-92. PubMed ID: 2871058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence and tardive dyskinesia.
    Soares K; McGrath J; Adams C
    Lancet; 1996 Jun; 347(9016):1696-7. PubMed ID: 8642986
    [No Abstract]   [Full Text] [Related]  

  • 51. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
    Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
    Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. alpha-Tocopherol treatment for tardive dyskinesia.
    Spivak B; Schwartz B; Radwan M; Weizman A
    J Nerv Ment Dis; 1992 Jun; 180(6):400-1. PubMed ID: 1593277
    [No Abstract]   [Full Text] [Related]  

  • 53. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whither vitamin E and tardive dyskinesia?
    Lohr JB; Lavori P
    Biol Psychiatry; 1998 Jun; 43(12):861-2. PubMed ID: 9627738
    [No Abstract]   [Full Text] [Related]  

  • 55. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
    Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin C and vitamin E for Alzheimer's disease.
    Boothby LA; Doering PL
    Ann Pharmacother; 2005 Dec; 39(12):2073-80. PubMed ID: 16227450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estrogen receptor activation and tardive dyskinesia.
    Turrone P; Seeman MV; Silvestri S
    Can J Psychiatry; 2000 Apr; 45(3):288-90. PubMed ID: 10779888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.